AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

BioNTech SE and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage ...

RESEARCHERS from SINTEF have developed a “simpler” low-cost carbon capture and storage (CCS) system for sequestering ...

BioNTech to acquire clinical-stage biotech company, Biotheus to boost oncology strategy: Mainz, Germany Friday, November 15, 2024, 14:00 Hrs [IST] BioNTech SE and Biotheus (Biothe ...

A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...

At the BioFuture 2024 conference held in New York in November, Seema Kumar, the CEO of Cure, described women’s health as something that has been directed at the “bikini area.” That “bikini” bias ...

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 billion) to buy biotech company Biotheus, a developer of cancer drugs. In a ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...